It’s not about outside speed, which SAVA shows plenty of, it’s inside speed, that’s where races are won, and there is not a biotech out there that takes the curves better than AVXL.
Precision medicine may take longer to find the right trial participants. It's possible, even likely, that Anavex isn't for everyone. That doesn't matter. If it's able to help even a small percentage of the Alzheimer's population, it should be approved by the FDA. I'd rather Dr. Missling take an extra 18 months to try and select the best pool of trial applicants than throw mud at a wall and hope something sticks with a trial design that doesn't incorporate precision targeting and genetic analysis.
News 
Market Data 
Discover 
